AMERICAN HEART JOURNAL. Long-term tissue coverage of a biodegradable polylactide polymer–coated biolimus-eluting stent: Comparative sequential assessment with optical coherence tomography until complete resorption of the polymer

Background: Biolimus-eluting stents (BESs) with a biodegradable polymer in abluminal coating achieve more complete coverage at 9 months compared with sirolimus-eluting stents (SESs) with a durable polymer, as assessed by optical coherence tomography (OCT). Whether this advantage persists or augments after complete resorption of the polymer (>12 months) is unknown.

JACC. Three Year Outcomes Of Chronic Total Occlusion Treatment With Biolimus Eluting Biodegradable Polymer Stent Versus Sirolimus Eluting Permanent Polymer Stent In the LEADERS All-comers Trial

JACC. Impact of Renal Impairment on Clinical and Angiographic Outcomes After Percutaneous Coronary Intervention with Drug-Eluting Stents: a Pooled Analysis of SIRTAX, LEADERS, and RESOLUTE All-Comers Trials

JACC. STEALTH I: 5-year Follow-up from a Prospective Randomized Study of Biolimus A9™-Eluting Stent with a Biodegradable Polymer Coating vs a Bare Metal Stent

EURO INTERVENTION. The three year follow-up of the randomised “all-comers” trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS)

Aims: The current study reports clinical outcomes at three year follow-up of the LEADERS clinical trial which was the first all-comers trial comparing a new generation biodegradable polymer biolimus drug-eluting stent (BES) with the first generation permanent polymer sirolimus-eluting stent (SES).

JACC: CARDIOVASCULAR INTERVENTIONS. Biodegradable Polymer Versus Permanent Polymer Drug-Eluting Stents and Everolimus- Versus Sirolimus-Eluting Stents in Patients With Coronary Artery Disease. 3-Year Outcomes From a Randomized Clinical Trial

Objectives: The aim of this study was to compare the 3-year efficacy and safety of biodegradable polymer with permanent polymer stents and of everolimus-eluting stents (EES) with sirolimus-eluting stents (SES).

EURO INTERVENTION. Implantation of the biodegradable polymer biolimus-eluting stent in patients with high SYNTAX score is associated with decreased cardiac mortality compared to a permanent polymer sirolimus-eluting stent: two year follow-up.

Background: The SYNTAX score (SXscore) has been shown to be an effective predictor of clinical outcomes in patients undergoing percutaneous coronary intervention (PCI).

EURO INTERVENTION. e-BioMatrix PMS Registry - A post market surveillance registry for the BioMatrix™ drug-eluting stent

Aims: The aim of the e-BioMatrix registry is to capture long-term clinical data of the BioMatrix stent system in relation to safety and effectiveness in a large population in routine clinical practice.

EURO INTERVENTION. Biolimus A9 drug eluting stents: comparative analyses of pharmacokinetics from three different stent platforms

Aims: Biolimus A9 is a proliferation signal inhibitors with unique properties that was specifically developed for coating on drug-eluting stents. Biolimus A9 is developed by the manufacturer Biosensors International and in the matrix with a biodegradable polylactic acid polymer is used in the second generation drug eluting stents. The aim of this study was to assess the pharmacokinetics of Biolimus A9 after elution from three different stent platforms.

EURO INTERVENTION. De novo coronary lesions treated with the novel polymer-free Biolimus-A9 coated stents: four- and twelve-month angiographic results from the prospective, randomised, multicentre BIOFREEDOM clinical trial

Aims: We report the results of the first-in-man evaluation of the BioFreedom (BF) Biolimus A9 (BA9) coated stent (Biosensors Int., Singapore), available in 2 different formulations: standard dose (SD: 15.6 μg/mm) and low dose (LD: 7.8 μg/mm).

EURO INTERVENTION. Long-term tissue coverage of a bioresorbable polylactide polymer-coated Biolimus-eluting stent: comparative sequential assessment with optical coherence tomography till complete resorption of the polymer

Aims: To assess the tissue coverage of a biolimus-eluting stent (BES) with bioresorbable polymer in abluminal coating at 24 months, when the polymer has been completely resorbed, as compared to a control sirolimus-eluting stent (SES) with durable polymer, using optical coherence tomography (OCT).

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. The pharmacokinetics of Biolimus A9 after elution from the BioMatrix II stent in patients with coronary artery disease: The Stealth PK Study

Objectives: This prospective, open-label multicenter study was conducted to assess the pharmacokinetics of Biolimus A9 after elution from BioMatrix II coronary stents. Recent clinical trials have demonstrated the efficacy and safety of Biolimus A9 eluted from different stent platforms. To date, the pharmacokinetics of Biolimus A9 in patients following the deployment of BioMatrix II stents has not yet been studied

EURO INTERVENTION. The outcome of bifurcation lesion stenting using a biolimuseluting stent with a bio-degradable polymer compared to a sirolimus-eluting stent with a durable polymer

Aims: This study investigated the differences in clinical outcomes between patients with bifurcation lesions (BL) treated with a biolimus-eluting stent (BES) with a biodegradable polymer, and a sirolimus-eluting stent (SES) with a durable polymer

ACUTE CARDIAC CARE. Biolimus-eluting biodegradable polymer-coated stent versus bare metal stent in acute ST-elevation and non-ST elevation myocardial infarction: Justification for biodegradable polymer-coated stent in acute coronary syndrome

Aims: We evaluated the efficacy and safety of a biolimus- eluting biodegradable polymer-coated stent (BES) in patients with ST-segment elevation and non ST-segment elevation acute myocardial infarction (AMI).

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Value of Age, Creatinine, and Ejection Fraction (ACEF Score) in Assessing Risk in Patients Undergoing Percutaneous Coronary Interventions in the All-Comers LEADERS Trial

Background— The age, creatinine, and ejection fraction (ACEF) score (age/left ventricular ejection fraction+1 if creatinine >2.0 mg/dL) has been established as an effective predictor of clinical outcomes in patients undergoing elective coronary artery bypass surgery; however, its utility in “all-comer” patients undergoing percutaneous coronary intervention is yet unexplored.